Author(s): Esposito V, Chiodini P, Viglietti R, Parrella R, Parrella G, , Esposito V, Chiodini P, Viglietti R, Parrella R, Parrella G,
Abstract Share this page
Abstract BACKGROUND: The hypothesis that fosamprenavir-including highly active antiretroviral therapy (HAART) regimens would be associated with few metabolic and hepatic side-effects was investigated. PATIENTS AND METHODS: An observational single-arm retrospective study was set up on a cohort of 139 human immunodeficiency virus (HIV)-infected patients, followed up at A.O.R.N. Cotugno Hospital, Naples, Italy, treated with antiretroviral regimens including fosamprenavir, in order to evaluate the safety of these regimens in relationship to hepatic and metabolic side-effects, also considering co-morbidities and other risk factors. RESULTS: Only seven patients met the criteria to reach the primary end-point (grade ≥ 3 adverse event) and none of them discontinued HAART therapy during the follow-up period. Eighty percent of the patients reached viral load <50 cp/μl at 48 weeks of observation. At the end of follow-up, no patient with fasting serum total cholesterol and/or fasting serum triglycerides above grade 3 was found, while 1 out of 114 (0.88\%) cases presented aspartate transaminase and alanine transaminase ≥ grade 3 and 1 out of 114 (0.88\%) cases had fasting serum glucose ≥ grade 3. One out of 137 patients developed a malignant neoplasm (0.73\%) and 4 (2.92\%) displayed newly diagnosed hypertension. CONCLUSION: Fosamprenavir-based regimens caused a low number of serious metabolic adverse events during a 48 week follow-up period, with a low incidence of co-morbidities and satisfying results in terms of viro-immunological response including for patients with already existing co-morbidities requiring other therapies.
This article was published in In Vivo
and referenced in Journal of AIDS & Clinical Research